uniQure N.V.

+2.00 (+5.59%)
Products, Regulatory

Uniqure Announces Enrollment Of Next Two Patients In Phase I/II Clinical Trial Of AMT-130

Published: 10/13/2020 11:36 GMT
Uniqure NV (QURE) - Uniqure Announces Enrollment of Next Two Patients in Phase I/ii Clinical Trial of Amt-130 for the Treatment of Huntington’s Disease.
Uniqure NV - Total of 4 Patients Enrolled in Study Thus Far, Including 2 Patients Treated With Amt-130 and Two Patients Who Received Imitation Surgery.
Uniqure NV -patient Enrollment Expected to Continue After Dsmb Meeting to Review 90day Followup Data on 2 New Patients&6-month Data on First 2 Patient.
Uniqure NV - Expect That Dsmb Review Will Take Place Early Next Year &patient Enrollment in 10-patient First Dose Cohort Will Be Completed by Mid-2021.